[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021013616A - Compuestos inhibidores de la masp y usos de estos. - Google Patents

Compuestos inhibidores de la masp y usos de estos.

Info

Publication number
MX2021013616A
MX2021013616A MX2021013616A MX2021013616A MX2021013616A MX 2021013616 A MX2021013616 A MX 2021013616A MX 2021013616 A MX2021013616 A MX 2021013616A MX 2021013616 A MX2021013616 A MX 2021013616A MX 2021013616 A MX2021013616 A MX 2021013616A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
inhibitor compounds
masp
diseases
Prior art date
Application number
MX2021013616A
Other languages
English (en)
Inventor
Simon Holton
Adrian Tersteegen
Donald Bierer
Carsten Terjung
Ingo Flamme
Thomas Neubauer
Dmitry Zubov
Jan Dreher
Cathleen Juhl
Marie Glatz
Lars Baumann
Thorsten Poethko
Jiancheng Xiong
Yibo Qiu
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2021013616A publication Critical patent/MX2021013616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los nuevos compuestos inhibidores de la peptidasa de serina asociada a la lectina de unión a la manosa (MBL) (MASP), así como a sus análogos y derivados, a los procesos para la preparación de estos, al uso de estos solos o en combinaciones para el tratamiento y/o la prevención de enfermedades y al uso de estos para la elaboración de medicamentos para el tratamiento y/o la prevención de enfermedades, especialmente para el tratamiento y/o la prevención de enfermedades renales y cardiovasculares y de lesiones por isquemia y reperfusión.
MX2021013616A 2019-05-07 2020-04-30 Compuestos inhibidores de la masp y usos de estos. MX2021013616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085791 2019-05-07
PCT/EP2020/062040 WO2020225095A1 (en) 2019-05-07 2020-04-30 Masp inhibitory compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2021013616A true MX2021013616A (es) 2021-12-10

Family

ID=70482659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013616A MX2021013616A (es) 2019-05-07 2020-04-30 Compuestos inhibidores de la masp y usos de estos.

Country Status (17)

Country Link
US (2) US11667675B2 (es)
EP (1) EP3966226A1 (es)
JP (1) JP7667091B2 (es)
KR (1) KR20220005556A (es)
CN (1) CN114585637B (es)
AR (1) AR119733A1 (es)
AU (1) AU2020268578A1 (es)
BR (1) BR112021021188A2 (es)
CA (1) CA3139209A1 (es)
CO (1) CO2021014755A2 (es)
IL (1) IL287753A (es)
MX (1) MX2021013616A (es)
PE (1) PE20220431A1 (es)
PH (1) PH12021552817A1 (es)
SG (1) SG11202111587VA (es)
TW (1) TW202108603A (es)
WO (1) WO2020225095A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011904A1 (en) * 2020-12-14 2022-06-15 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CA3200103A1 (en) 2020-11-04 2022-05-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
MXPA03005625A (es) 2000-12-21 2004-12-03 Scripps Research Inst Analogos de tiocoralina y be-22179.
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2006518749A (ja) 2003-02-21 2006-08-17 タノックス インコーポレーテッド 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2465535A1 (en) 2004-06-10 2012-06-20 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
HUP0900319A2 (en) * 2009-05-25 2011-01-28 Eotvos Lorand Tudomanyegyetem New peptides, method of producing therof and use thereof
KR20120083218A (ko) * 2009-05-25 2012-07-25 엠티에이 테르메제투도만이 쿠타토코즈폰트, 엔지몰로지아이 인테젯 신규한 펩티드, 신규한 펩티드의 제조 방법 및 용도
US20120282285A1 (en) * 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2011275825A1 (en) 2010-07-09 2013-02-07 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
KR20150031298A (ko) 2012-06-18 2015-03-23 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP2875003B1 (de) 2012-07-20 2016-11-16 Bayer Pharma Aktiengesellschaft Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung
AU2014229020B2 (en) 2013-03-15 2017-09-28 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
AU2014332021B2 (en) 2013-10-07 2020-05-07 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
CN107075574A (zh) 2014-06-27 2017-08-18 领导医疗有限公司 铁调素和微型铁调素类似物及其用途

Also Published As

Publication number Publication date
BR112021021188A2 (pt) 2021-12-14
CN114585637A (zh) 2022-06-03
WO2020225095A1 (en) 2020-11-12
CN114585637B (zh) 2025-04-15
AU2020268578A1 (en) 2022-02-03
PE20220431A1 (es) 2022-03-29
CO2021014755A2 (es) 2021-11-19
US20210246166A1 (en) 2021-08-12
JP7667091B2 (ja) 2025-04-22
KR20220005556A (ko) 2022-01-13
AR119733A1 (es) 2022-01-05
US20240124522A1 (en) 2024-04-18
SG11202111587VA (en) 2021-11-29
IL287753A (en) 2022-01-01
CA3139209A1 (en) 2020-11-12
US11667675B2 (en) 2023-06-06
TW202108603A (zh) 2021-03-01
JP2022532069A (ja) 2022-07-13
EP3966226A1 (en) 2022-03-16
PH12021552817A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
MX2021013616A (es) Compuestos inhibidores de la masp y usos de estos.
DOP2018000004A (es) Derivados de oxopiridina sustituidos
PH12018500259A1 (en) Muscarinic agonists
JOP20170105B1 (ar) مشتقات بيريدينيل تريازول مستبدلة بأميد واستخدامها
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
MX2017007426A (es) Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MX2017011000A (es) Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
MX2017014035A (es) Formas solidas novedosas.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
MX394123B (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos
CL2018002128A1 (es) Composiciones y métodos para el tratamiento de heridas crónicas
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
PH12017501668A1 (en) Bace1 inhibitors
ZA202207539B (en) Composition and methods of manufacture
EA201890911A1 (ru) Комбинация тразодона и габапентина для лечения боли
EA201890209A1 (ru) Композиция, содержащая танины
MX388336B (es) Composicion farmacéutica oftálmica, procesos de preparación y usos de las mismas
EA202091524A1 (ru) Ингибиторы рецептора, активируемого протеазой 2